OKYO Pharma Limited

LSE:OKYO Rapporto sulle azioni

Cap. di mercato: UK£23.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

OKYO Pharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

OKYO Pharma has been growing earnings at an average annual rate of 39.4%, while the Biotechs industry saw earnings growing at 7.2% annually.

Informazioni chiave

39.4%

Tasso di crescita degli utili

62.4%

Tasso di crescita dell'EPS

Biotechs Crescita del settore11.5%
Tasso di crescita dei ricavin/a
Rendimento del capitale proprion/a
Margine netton/a
Ultimo aggiornamento sui guadagni30 Sep 2022

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

Nov 26
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?

Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

Jan 27
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

Sep 22
Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation

We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

Mar 17
We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth

We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

Dec 02
We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow

Ripartizione dei ricavi e delle spese

Come OKYO Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

LSE:OKYO Ricavi, spese e utili (GBP Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 220-703
30 Jun 220-502
31 Mar 220-401
31 Dec 210-401
30 Sep 210-400
30 Jun 210-300
31 Mar 210-300
31 Dec 200-100
30 Sep 200000
30 Jun 200-100
31 Mar 200-100
31 Dec 190-301
30 Sep 190-402
30 Jun 190-402
31 Mar 190-402
31 Dec 180-301
30 Sep 180-201
30 Jun 180-1101
31 Mar 180-2000
31 Dec 170-2000
30 Sep 170-1900
30 Jun 170-1000
31 Mar 170000
31 Dec 160000
30 Sep 160010

Guadagni di qualità: OKYO is currently unprofitable.

Margine di profitto in crescita: OKYO is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: OKYO is unprofitable, but has reduced losses over the past 5 years at a rate of 39.4% per year.

Accelerare la crescita: Unable to compare OKYO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: OKYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).


Rendimento del capitale proprio

ROE elevato: OKYO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate